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Haematuria has been traditionally considered as a benign hallmark of some glomerular dis-
eases; however new studies show that haematuria may decrease renal function.
Objective
To determine the influence of haematuria on the rate of chronic kidney disease (CKD) pro-
gression in 71 proteinuric patients with advanced CKD (baseline eGFR <30 mL/min) during
12 months of follow-up.
Results
The mean rate of decline in eGFR was higher in patients with both haematuria and protein-
uria (haemoproteinuria, HP, n=31) than in patients with proteinuria alone (P patients, n=40)
(-3.8±8.9 vs 0.9±9.5 mL/min/1.73m2/year, p<0.05, respectively). The deleterious effect of
haematuria on rate of decline in eGFR was observed in patients <65 years (-6.8±9.9 (HP)
vs. 0.1±11.7 (P) mL/min/1.73m2/year, p<0.05), but not in patients >65 years (-1.2±6.8 (HP)
vs. 1.5±7.7 (P) mL/min/1.73m2/year). Furthermore, the harmful effect of haematuria on
eGFR slope was found patients with proteinuria >0.5 g/24 h (-5.8±6.4 (HP) vs. -1.37± 7.9
(P) mL/min/1.73m2/year, p<0.05), whereas no significant differences were found in patients
with proteinuria < 0.5 g/24 h (-0.62±7.4 (HP) vs. 3.4±11.1 (P) mL/min/1.73m2/year). Multi-
variate analysis reported that presence of haematuria was significantly and independently
associated with eGFR deterioration after adjusting for traditional risk factors, including age,
serum phosphate, mean proteinuria and mean serum PTH (β=-4.316, p=0.025).
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Conclusions
The presence of haematuria is closely associated with a faster decrease in renal function in
advanced proteinuric CKD patients, especially in younger CKD patients with high protein-
uria levels; therefore this high risk subgroup of patients would benefit of intensive medical
surveillance and treatment.
Introduction
Chronic kidney disease (CKD) is a global public health problem, as result of its growing preva-
lence and costs, and the higher risk to progress to end-stage renal disease (ESRD), cardiovascu-
lar disease and death [1, 2]. The rate of progression of CKD may be affected by several factors
[3], including age, gender, proteinuria, hypertension, diabetes mellitus and mineral-bone me-
tabolism biomarkers (fibroblastic growth factor 23, serum phosphate and parathyroid hor-
mone (PTH) levels) [4]. However, these classic risk factors cannot account for some findings.
Therefore, it is necessary to identify more relevant risk markers to identify those patients at
higher risk to progress faster to ESRD.
Haematuria is defined as the presence of red blood cells (RBCs) in urine. Haematuria is a
common finding in various glomerular diseases, such as IgA nephropathy (IgAN), Alport syn-
drome and thin basement membrane disease [5]; however its presence is usually not men-
tioned in large epidemiological studies and little is known about its role on CKD progression
[6–7]. After decades of considering haematuria as a benign clinical manifestation of glomerular
diseases, without real consequences on renal function and long-term prognosis, new evidences
pointed its negative implications on the progression of renal disease [8–9]. Thus, persistent
asymptomatic isolated microscopic haematuria was significantly associated with increased risk
of ESRD in 1 million young Israeli adults after more than 20 years of follow up [8]. In addition,
persistent glomerular haematuria in kidney donors was associated with CKD progression at
2.3 years after donation [10]. Negative association between macroscopic haematuria and long-
term renal prognosis have been also reported in IgAN patients [9, 11, 12], although there are
contradictory results [9,13–15]. On the other hand, it is well known that macroscopic haema-
turia may leads acute kidney injury (AKI) in IgAN patients and excessively anticoagulated pa-
tients (INR>3.0, the so-called warfarin-related nephropathy (WRN)), with an incidence of
30% and 20%, respectively [9,16]. Interestingly, recent evidences show that up to 25% of IgAN
patients and 66%WRN patients did not recover baseline renal function after macroscopic
haematuria-associated AKI, leading to adverse long-term outcomes [9, 16]. Furthermore, the
KDOQI (Kidney Disease Outcomes Quality Initiative) and KDIGO (Kidney Disease: Improv-
ing Global Outcome) guidelines recommend to assess every CKD patient with dipstick [17],
although they not recommend further monitoring or treatment in patients with glomerulone-
phritis and isolated microscopic haematuria. However, these guidelines acknowledge that
IgAN with haematuria and minimal proteinuria is a progressive disease [18]. In contrast, in
ANCA-associated vasculitis, persistent microscopic haematuria did not show a clear repercus-
sion on glomerular filtration rate at 1 year follow up [19]. Therefore, the real impact of haema-
turia on CKD progression remains unknown.
To date, the relation between the presence of haematuria and decline of renal function has
been analyzed in subjects at early CKD stages, excluding systematically to those patients with
estimated glomerular filtration rate (eGFR)<45 ml/min [9, 20]. However, advanced CKD
are of special interest in clinical practice due to their rising prevalence and higher associated
Haematuria and Progression of Advanced Proteinuric Kidney Disease
PLOS ONE | DOI:10.1371/journal.pone.0128575 May 27, 2015 2 / 12
comorbidities. For that reason, in the present article we aimed to analyze the effect of haema-
turia on the rate of progression of renal function in advanced proteinuric CKD patients over
one year of follow up.
Material and Methods
Patients
In this retrospective observational longitudinal study, we analyzed data from 300 patients with
advanced CKD (stages 4 and 5) followed between 2006 and 2010 in the Renal Unit at Gregorio
Marañón Hospital, Madrid, Spain [21]. Patients provided written informed consent. Gregorio
Marañón Hospital Ethics Committee approved the study. The investigation conforms to the
principles outlined in the Declaration of Helsinki. The exclusion criteria were: (1) proteinuria
negative (<0.03 g in 24-hour urinary excretion), (2) haematuria data non recorded, (3) follow
up fewer than 6 months and fewer than 4 determinations of eGFR (calculated using Modifica-
tion of Diet in Renal Disease [MDRD] study 4-item equation) [22], (4) baseline eGFR>30mL/
min, (5) patients with malignancies or infections during the follow up, and (6) patients with au-
tosomal dominant polycystic kidney disease, urological malignancies or concurrent urinary in-
fection (in order to avoid the possible inference of non-glomerular haematuria over glomerular
haematuria detection). Finally 71 patients were included and prospectively followed up for
11.9 ± 5.4 months. Patients were categorized in 2 groups according to the presence of haema-
turia. Patients were considered haemoproteinuric (HP) when presented both haematuria and
proteinuria, whereas proteinuric patients (P) presented proteinuria alone.
Demographic data and laboratory values were recorded along the study period. In each pa-
tient, we recorded the values for serum creatinine, proteinuria, phosphate, calcium, uric acid,
PTH, and 24-hour urinary excretion of urea nitrogen in each determination to calculate the
mean value for each variable over time. Treatment was also recorded, including antihyperten-
sive drugs, statin therapy, erythropoiesis-stimulating agents, and iron supplements. High blood
pressure was defined as an average systolic/diastolic blood pressure of 130/85 mmHg or greater
or current use of antihypertensive medication, independently of blood pressure levels. Protein-
uria was defined as>0.03 g protein levels in 24-hour urinary excretion determination. CKD
progression was assessed as the slope of the regression line of all eGFR measurements (mL/
min) over time (years) adjusted for body surface (1.73m2) and expressed as mL/min/1.73m2/
year. Therefore, the faster progression has a more negative slope.
Laboratory Measurements
Freshly voided samples were collected for urinalysis. Laboratory measurements were made
using standardized automated methods, as previously reported [20]. The presence of haema-
turia was assessed with dipstick, and then confirmed with microscopic examination in each
patient and every clinical visit. Patients were considered haematuric if presented at least 3
positive determinations.
Statistical Analysis
Normally distributed values are expressed as mean±SD; non-normally distributed values are
expressed as median±IQR. The differences in qualitative variables were examined using the
chi-square test for categorical variables. Continuous variables were compared using the Stu-
dent’s t-test for independent samples after verifying the normality of distribution using the
Kolmogorov-Smirnov test or by analysis of variance (ANOVA) when comparing more groups.
A linear model was constructed to identify the relationship between different variables.
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Multivariate analysis (lineal regression) was performed to determine the associations between
the eGFR slope and the predisposing risk factors. On the multivariate analysis we used the
serum PTH logarithm in order to correct its asymmetric distribution. All statistical analyses
were conducted using SPSS for Windows, version 15 (Chicago,Illinois, USA). Statistical signifi-
cance was considered at p<0.05.
Results
Demographic, clinical characteristic and baseline biochemical values according to the presence
of HP are summarized on Table 1. The mean annual eGFR slope was -1.12±9.38 mL/min/
1.73m2/year. None of our patients presented documented macrohaematuria during the follow
up. The aetiology of CKD was diabetic nephropathy in 19 patients (26.8%, 10 P vs. 9 HP), fol-
lowed by nephroangiosclerosis in 15 patients (21%, 11 P vs. 4 HP), glomerular disease in 10 pa-
tients (14.1%, 5 P vs. 5 HP), tubulointerstitial nephritis in 10 patients (14.1%, 6 P vs. 4 HP) and
unknown in 17 patients (24%, 5 P vs. 12 HP). No significant differences in demographical,
CKD aetiology or baseline clinical data were observed between HP and P patients. Eleven hae-
maturic patients (32.4%) were under antiplatelet drug therapy whereas 14 non-haematuric
Table 1. Characteristics of patients according to the presence of haematuria.
HP (n = 31) P (n = 40) All (n = 71) P value
Clinical characteristics
Age (years) 62.9±16.9 66.9±13.0 65.1±14.85 0.27
Gender (Male, %) 20(57.5) 23(64.5) 43(56.3) 0.68
Hypertension (Yes, %) 26 (83.9) 36 (90) 62 (87.3) 0.34
Number of antihypertensive drugs (n) 2.1±1.5 2.7±1.5 2.5±1.5 0.11
RAAS inhibitors (Yes, %) 17(50) 22 (61.1) 39 (55.7) 0.24
Diabetes Mellitus (Yes, %) 12 (38.7) 14 (35) 26 (36.6) 0.47
Body mass index (kg/m2) 27.2±4.7 29.6±6.6 28.5±5.9 0.09
Charlson comorbidity index 6.03±2.52 5.18±1.75 5.55±2.15 0.10
Mean number of eGFR determinations per patient (n) 7.7±3.2 7.3±2.5 7.5±2.7 0.50
Follow up (months) 11.56±5.74 12.17±5.1 11.9±5.35 0.79
Age (years) 62.9±16.9 66.9±13.0 65.1±14.85 0.27
Baseline levels
Serum creatinine (mg/dL) 3.32±0.64 3.13±0.66 3.2±0.65 0.23
eGFR (mL/min/1.73m2) 19.25±5.47 19.78±4.63 19.6±4.99 0.65
Serum phosphate (mg/dL) 5.1 ±5.9 4.1±0.65 4.5±3.9 0.38
Serum PTH(ng/L) 203[101, 421] 166[124, 283] 185[115, 310] 0.83
Serum calcium (mg/dL) 8.67±0.63 8.4±0.77 8.5±0.7 0.10
Serum haemoglobin (g/dL) 12.4±1.7 11.8±1.4 12.1±1.56 0.11
Proteinuria (g/24 h) 1.11±1.69 0.89±1.38 0.98±1.51 0.55
Urinary excretion of urea nitrogen (g/24h) 16.86±5.82 18.08±5.83 17.5±5.8 0.39
Mean determination during follow up
Proteinuria (g/24 h) 1.06±1.33 0.99±1.27 1.02±1.29 0.81
Serum Phosphate (mg/dL) 4.17±0.77 3.98±0.56 4.07±0.66 0.22
Serum PTH (ng/L) 205[118, 466] 216[173, 322] 208[171, 333] 0.83
Mean Annual eGFR slope (mL/min/1.73m2/year) -3.76±8.68 0.92±9.49 -1.12±9.38 0.03
Results are expressed as mean ± SD, n(%) or median [IQR]. HP, Haemoproteinuria; P, proteinuria alone; eGFR, estimated glomerular ﬁltration rate; PTH,
parathyroid hormone; RAAS inhibitors, renin angiotensin aldosterone system inhibitors.
doi:10.1371/journal.pone.0128575.t001
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patients (37.8%) received this treatment (p = 0.41). During the follow up, 9 patients reached
ESRD in the HP group and 8 in the P group (29% HP vs. 20% P; p = 0.27). Interestingly, HP
patients presented higher mean rate of decline in eGFR than patients with proteinuria alone
(-3.8±8.7 vs. 0.9±9.5 mL/min/1.73m2/year), so they progressed significantly faster to ESRD
(p = 0.036) (Table 1).
We then analyzed whether there was a different effect of haematuria on eGFR decline ac-
cording to gender. Our results showed that HP patients progressed faster than those with pro-
teinuria alone, independently of gender (Fig 1). Women with HP tended to progress faster
than those with proteinuria alone, although no significant differences were found (-3.83±7.3
vs. 2.52±12.5 mL/min/1.73m2/year, p = 0.084) (Fig 1).
We found a significant interaction between the presence of haematuria and age on the pro-
gression of CKD. Thus, the effect of haematuria on rate of decline in eGFR was observed in pa-
tients<65 years (-6.8±9.9 (HP) vs. 0.1±11.7 (P) mL/min/1.73m2/year, p<0.05), but not in
patients>65 years (-1.2±6.8 (HP) vs. 1.5±7.7 (P) mL/min/1.73m2/year) (Fig 2). Furthermore,
eGFR decreased faster in younger HP patients than in older HP patients, although no signifi-
cant differences were found (−6.8±9.9 vs. -1.2± 6.8 mL/min/1.73m2/year respectively,
p = 0.07). Patients>65 years with proteinuria alone remained stable or even improved the
eGFR slope (Fig 2). We did not observed significant differences in mean proteinuria, serum
mean phosphate or serum mean PTH between HP and P groups according to age (Table 2).
To determine whether the effect of haematuria on eGFR slope was associated to proteinuria,
our patients were equally distributed into two groups according to the median proteinuria value
obtained along the study. Thus, patients were divided into two groups: patients with
proteinuria< 0.5 g/24 h or patients with proteinuria> 0.5 g/24 h. The harmful effect of haema-
turia on eGFR slope was found in patients with proteinuria>0.5 g/24 h (-5.8±6.4 (HP) vs. -1.37
± 7.9 (P) mL/min/1.73m2/year, p<0.05), whereas no significant difference was found in those
patients with proteinuria<0.5 g/24 h (-0.62±7.4 (HP) vs. 3.4±11.1 (P) mL/min/1.73m2/year)
Fig 1. Differences in the mean annual eGFR slope by gender and presence of haematuria. Values are
expressed as mean±SD.
doi:10.1371/journal.pone.0128575.g001
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(Fig 3). No differences were found between haematuric and non haematuric patients in mean
proteinuria, serummean phosphate or serum mean PTH, gender or hypertension according
with proteinuria degree (Table 3).
Univariate analysis reported that progression of eGFR was inversely associated with mean
serum phosphate, serum PTH, proteinuria, and haematuria and directly associated with mean
serum calcium (Table 4). There were no significant differences for age, gender, hypertension,
the number of antihypertensive drugs, and 24-hour urinary excretion of urea nitrogen in the
progression of CKD.
To clarify whether haematuria was independently associated with eGFR decline in these pa-
tients, we performed a multiple regression analysis. Variables that were expected to influence
Fig 2. Differences in the mean annual eGFR slope by age and presence of haematuria. NS, non
significant. Values are expressed as mean±SD.
doi:10.1371/journal.pone.0128575.g002
Table 2. Differences in analytical data by age and presence of haematuria.
Analytical data <65 years >65 years
HP (n = 14) P (n = 17) p value HP (n = 17) P (n = 23) p value
Mean Annual GFR slope (mL/min/1.73m2/year) -6.9±9.9 0.1±11.7 <0.05 -1.2±6.8 1.5±7.68 0.25
Mean proteinuria (g/24 h) 1.37±1.7 1.31±1.27 0.66 0.80±0.9 0.74±1.23 0.87
Mean serum phosphate (mg/dL) 4.29±0.96 4.02±0.50 0.31 4.08±0.58 3.95±0.62 0.50
Mean serum PTH (ng/L) 199 [140, 329] 225 [134, 315] 0.52 207 [118, 474] 214 [179, 333] 0.22
Results are expressed as mean ± SD or median [IQR]
HP, Haemoproteinuria; P, proteinuria alone
doi:10.1371/journal.pone.0128575.t002
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progression of eGFR (mean serum phosphate, serum PTH, proteinuria and mean serum calci-
um), as well as the presence of haematuria, were included in the multiple regression analysis.
In such model, mean proteinuria (β = -2.47 p<0.005), mean serum PTH (β = -4.83, p<0.005)
and haematuria (β = -4.316, p<0.05) persisted as independent predictors of eGFR deterioration
(Table 5).
Discussion
In the current study we demonstrated that haematuria is a significant and independent predic-
tor of eGFR deterioration in patients with advanced CKD. Furthermore, we found that the as-
sociation between haematuria and the rate of decline in eGFR was mainly restricted to younger
CKD patients with high proteinuria levels.
Fig 3. Differences in the mean annual eGFR slope in patients according to proteinuria levels and
presence of haematuria. Values are expressed as mean±SD.
doi:10.1371/journal.pone.0128575.g003
Table 3. Differences in analytical data by proteinuria and presence of haematuria.
Analytical data Proteinuria < 0.5 g/ 24 h Proteinuria > 0.5g /24 h
HP (n = 18) P (n = 19) p value HP (n = 16) P (n = 17) p value
Gender (male) 13 (57.9%) 11 (72.2%) 0.49 9(56.3%) 10 (58.8%) 0.58
Hypertension (yes, %) 14 (77.8%) 17 (89.5%) 0.41 14(87.5%) 16(94.1%) 0.6
Mean Annual GFR slope (mL/min/1.73m2/year) -1.5±9.4 3.4±11.1 0.15 -5.7±6.4 -0.62±7.4 0.042
Mean proteinuria (g/24 h) 0.18±0.16 0.12±0.17 0.29 1.85±1.47 1.95±1.13 0.84
Mean serum phosphate (mg/dL) 4.02±0.53 3.9±0.57 0.46 4.05±0.61 4.3±0.9 0.33
Mean serum PTH (ng/L) 234[114, 340] 196 [173, 295] 0.71 232 [178,484] 219 [148, 329] 0.34
Results are expressed as mean ± SD or median [IQR]
HP, Haemoproteinuria; P, proteinuria alone
doi:10.1371/journal.pone.0128575.t003
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Althought hematuria is a common manifestation of glomerular damage, associated with dif-
ferent renal diseases, its relation with CKD progression has traditionally been forgotten in the
largest epidemiological studies [6, 7]. This fact may be due to the difficult detection and quanti-
fication of glomerular haematuria [23]. Recent reports have highlighted the negative implica-
tions of haematuria on renal function deterioration [8, 9]. Thus, it has been reported both
acute and long-term worsening of renal function during episodes of macroscopic haematuria
in IgAN andWRN patients [9, 16]. In the same line, the largest cohort reported by Vivante
et al, showed that persistent asymptomatic isolated microscopic haematuria was significantly
associated with increased risk of ESRD after 22 years of follow-up in 1 million young adults
[8]. Similarly, persistent glomerular haematuria in kidney donors has been reported as a risk
factor for proteinuria and deterioration of renal function at 2.3 years after donation [10]. Goto
et al. showed that mild haematuria was associated with the risk of ESRD during 10-year follow-
up of IgAN patients and included haematuria in the algorithm to predict renal outcome in
these patients [24]. Mild haematuria (1–29 RBCs/high-power field) was the best predictor of
renal deterioration in patients with eGFR> 60 mL/min/1.73m2, without severe proteinuria
(<100 mg/dL), with an OR of 2.3 (95% CI, 1.2–4.3) for renal deterioration at 10-year follow up
[25]. Furthermore, disappearance of both haematuria and proteinuria has been proposed as
clinical remission markers on IgAN [26] and it is commonly used in clinical trials [20, 27]. In
addition, the most influential renal guidelines advised that IgAN with haematuria and minimal
proteinuria may be a progressive disease [18]. Nevertheless, there are several contradictory re-
ports, ruling out the repercussion of microhaematuria on the outcome of IgA nephropathy,
specially in patients with minimal or no proteinuria [28] or even mild proteinuria [29].
Table 4. Univariate analysis by Lineal Regression. Factors associated with the rate of eGFR deterioration.
β 95% CI p value
Age (years) 0.09 -0.06, 0.24 0.24
Gender (Male) 1.90 -2.655, 6.45 0.41
Hypertension (Yes) 2.07 -4.633, 8.78 0.54
Mean proteinuria (g/24 h) -2.89 -4.502, -1.29 <0.001
Mean serum phosphate (mg/dL) -5.24 -8.393, -2.09 0.001
Mean serum PTH (ng/L) -0.02 -0.03, -0.01 0.010
Mean serum calcium (mg/dL) 4.64 0.37, 8.92 0.033
Urinary excretion of urea nitrogen (g/24h) 0.27 -0.12, 0.66 0.18
Antihypertensives (Yes) -0.33 -1.81, 1.15 0.66
Haemoproteinuria (Yes) -4.69 -9.05, -0.32 0.035
PTH: parathyroid hormone.
doi:10.1371/journal.pone.0128575.t004
Table 5. Multivariate analysis by Lineal Regression. Factors associated with the rate of
eGFR deterioration.
β 95% CI p value
Mean proteinuria (g/24 h) -2.47 -3.96, -0.99 0.001
Mean serum PTH (ng/L) -4.83 -7.82, -1.85 0.002
Haemoproteinuria (Yes) -4.32 -8.09, -0.54 0.026
Intercept 29.38 13.29, 45.47 0.001
Adjusted R2 = 0.2907. PTH: parathyroid hormone.
doi:10.1371/journal.pone.0128575.t005
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Furthermore, no relation between persistent microscopic haematuria and renal function was
reported in patients with ANCA vasculitis [19]. Therefore, the real role of microhaematuria on
renal function outcome remains uncertain. In our study, haematuria was significantly associat-
ed with a faster progression of renal function decline in advanced CKD patients. Importantly,
in our study, the effect of haematuria on eGFR deterioration remained significant after adjust-
ing for traditional risk factors, including proteinuria. This fact may indicate the role of haema-
turia as a glomerular disease activity marker in patients with chronic renal damage, as reported
in advanced CKD patients. To our knowledge, this is the first study analyzing the role of hae-
maturia on the progression of renal disease in patients with advanced CKD.
Haematuria could induce glomerular damage by the cytotoxic, oxidant and inflammatory
effects of haemoglobin (Hb) and Hb- related molecules, such, heme and iron [30, 31]. Erythro-
cyte egression across the glomerular filtration barrier (GFB) induces mechanical stress, leading
to a distorted cytoskeleton that is unable to keep Hb lock inside erythrocyte cytoplasm. As con-
sequence, Hb is released from RBC to the urinary space, being then uptaked by tubular epithe-
lial cell where is further transformed into heme and globin. Free heme is extremely toxic,
promoting lipid oxidation from intracellular membranes, denaturing proteins, or inducing
chemokines release, as monocyte chemoattractant protein [30, 32, 33]. This heme-induced oxi-
dant and inflammatory status could be involved in the faster progression of eGFR decline ob-
served in our study in CKD patients with haematuria. However, new studies are necessary to
validate this hypothesis. Importantly, we also found that the harmful effect of haematuria on
eGFR slope was maximized in patients with high proteinuria levels. It is probable that protein-
uria, by increasing oxidative stress and inflammation, may potentiate the injurious actions
5promoted by haematuria, thus leading to a more harmful environment that may accelerate
progression of renal disease, as we have observed. Therefore, our findings suggest that haema-
toproteinuric patients would benefit of a more intensive medical surveillance and treatment.
The reduction of eGFR is considered a biological process associated to aging [34]. However,
ESRD progression is slow in elderly patients, probably because they present a less aggressive
clinical presentation, with low proteinuria, and more easily controlled hypertension [35]. This
fact could explain our results, where HP patients> 65 years progressed slowly as compared
with the youngest HP patients. Haematuria bouts are much more frequent on early CKD stages
of IgAN [14], when glomerulosclerosis is still not present, explaining our findings. A number
of reports suggest that haematuria is more intense and recurrent on early CKD stages (1 to 3),
pointing glomerular disease activity flares. From these early CKD stages, episodic bouts of hae-
maturia may then progress towards a persistent and low-grade haematuria on advanced CKD,
secondary to chronic histological lesions (as fibrosis), maintaining inflammatory stress and
promoting CKD progression.
CKD is more frequent in men and male gender has been classically considered as a risk fac-
tor for CKD. In agreement with previous reports [8, 36, 37], our data show that the presence of
haematuria was more frequent in men. However, we did not find differences on mean annual
eGFR slope in HP patients according to gender. Thus, we found that the presence of HP in-
creased the progression of eGFR in both men and women, but significant differences were not
reported between genders. Haematuric males presented worse outcome than haematuric fe-
males in Alport syndrome, thin glomerular basement nephropathy, C3 glomerulopathy (such
CFHR5 nephropathy) [36], and Fabry disease [38], whereas no significant differences were re-
ported in IgAN [37]. Therefore new studies are necessary to address this issue.
It is important to note that the principal limitation of our study is that we could not analyze
the effect of the intensity of haematuria on decline of renal function, ie, as a categorical variable
quantifying the impact of its intensity. Haematuria was detected by dipstick in the major part
of our patients, being unable to quantify the intensity of haematuria. Furthermore, although
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haematuria was confirmed by microscopic examination in all subjects, quantification of RBC
in urine was not reported in a high number of patients. Another limitations of the study are
that our results cannot be extrapolated to a more general population, such as patients with less
renal damage (CKD stages 1–3), and the small sample size; therefore the results obtained in
this study should be confirmed in new studies, with a higher sample size, to corroborate the
negative effects of haematuria on progression of renal disease in patients with CKD.
In conclusion, advanced proteinuric CKD patients with haematuria progressed significantly
faster to ESRD as compared with patients with proteinuria alone. Younger patients with high
proteinuric levels seem to be more sensible to the effect of haematuria. Haematuria, in addition
to proteinuria and high serum PTH levels were associated with renal function deterioration.
For that reasons it seems mandatory to improve glomerular haematuria detection and the use
of quantification techniques to identify patients at higher risk of CKD progression.
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